Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II by Miller, R
  Current Neuropharmacology, 2009, 7, 315-330  315 
  1570-159X/09 $55.00+.00  ©2009 Bentham Science Publishers Ltd. 
Mechanisms  of  Action  of  Antipsychotic  Drugs  of  Different  Classes,  
Refractoriness  to  Therapeutic  Effects  of  Classical  Neuroleptics,  and  
Individual Variation in Sensitivity to their Actions: PART II 
R. Miller
* 
Otago Centre for Theoretical Studies in Psychiatry and Neuroscience (OCTSPAN), Department of Anatomy and Struc-
tural Biology, School of Medical Sciences, University of Otago, P.O.Box 913, Dunedin, New Zealand 
Abstract: Rapid-onset psychotic rebound is uncommon on discontinuation of most antipsychotic drugs, as might be ex-
pected for antipsychotic drugs with (hypothetically) indirect actions at their final target receptors. Rapid-onset psychosis 
is more common on withdrawal of clozapine, which might be expected if its action is direct. Drugs other than clozapine 
(notably thioridazine) may have hitherto unrecognised similarities to clozapine (but without danger of agranulocytosis), 
and may be useful in treatment of refractory psychosis. Quetiapine fulfils only some criteria for a clozapine-like drug. 
Clinical response to neuroleptics varies widely at any given plasma level. Haase’s “neuroleptic threshold” concept sug-
gests that the dose producing the slightest motor side effects produces most or all of the therapeutic benefit, but analyses 
presented here suggest that antipsychotic actions are not subject to a sharp “all-or-none” threshold but increase over a 
small dose range. This concept could provide a method for quantitative determination of individualized optimal doses. 
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1.  WITHDRAWAL-EMERGENT  PSYCHOSIS:  
EVIDENCE AND THEORY 
  What happens when antipsychotic drugs are withdrawn, 
or the dose reduced? This question is not fully resolved. Em-
pirically, for many cases previously receiving standard neu-
roleptic  drugs,  it  is  documented  that,  if  relapse  occurs,  it 
does not do so immediately, but in a probabilistic manner, 
sometime in the next one or two years (see PART I, Sect. 5). 
The cumulative rate of relapse over  this period may vary, 
according to clinical state at the time of withdrawal [50], in-
patient versus out-patient status of the subjects, whether the 
change  is  sudden  or  gradual  [123],  and  in  relation  to  life 
events [5]. In a second pattern, documented as “supersensi-
tivity  psychosis”  relapse  may  occur  more  rapidly;  and,  as 
summarised in PART I (Sect 7), may be the consequence of 
progressive reduction  in the number of striatal  cholinergic 
interneurones in some patients, during prolonged treatment 
with  neuroleptic  drugs.  That  this  is  not  due  to  reversible 
changes in receptor numbers is indicated by the relative per-
manence of the condition, once it has appeared [14,15]. 
  In the case of clozapine there is evidence of a third pat-
tern of events, indicative of direct pharmacodynamic rather 
than more complex processes at the psychological level: De-
veloping within days of the last dose of clozapine there may 
be a sudden “rebound”, which may include agitation, abnor-
mal movements,  and florid psychosis, often worse than in 
the original psychotic illness [3,31,113]. This may occur in  
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at least 50% of patients after sudden discontinuation [107]. If 
clozapine is re-introduced to check the rapid worsening in 
condition, the dose needed is substantially larger than when 
initially prescribed [90]. Patients receiving drugs with anti-
cholinergic  potency  (including  both  antidepressants  and 
standard  antipsychotic  drugs),  in  addition  to  clozapine  are 
less likely to experience rebound psychosis than those not so 
“protected” (21% vs 71% of patients, in a retrospective Fin-
nish study [24,107]). The incidence of such rebound psycho-
sis is much lower after short (28 day) courses of clozapine 
[108],  than  in  other  studies  where  clozapine  was  used  for 
longer periods. The rebound psychosis, if it occurs, is tran-
sient, lasting about one month, with improvement thereafter 
[107].  In  advanced  Parkinson’s  disease  patients,  sudden 
withdrawal of clozapine may lead to severe exacerbation of 
the original parkinsonian symptoms [133], and clozapine is 
not easily replaced by other atypical drugs, such as risperi-
done or olanzapine [40]. In Western countries clozapine is 
now generally reserved for refractory patients, in whom this 
sudden rebound psychosis might be attributed to the resur-
gence  of  the  original  illness.  However,  when  clozapine  is 
given  for  some  time  to  patients  known  to  be  neuroleptic-
responsive,  its  withdrawal  is  even  then  accompanied  by 
quick-onset  rebound  psychosis  [84].  Such  reactions  after 
clozapine withdrawal are actually more common in patients 
previously responsive to neuroleptics than in refractory pa-
tients [82]. If the withdrawal is achieved by “cross-tapering” 
with typical drugs, psychotic relapse after the last dose of 
clozapine is given may still occur also within a few days, 
despite  the  expected  protection  by  the  standard  drug.  Re-
placement by the atypical drug risperidone (which has little 
cholinergic  potency)  has  little  protective  effect  [122],  al-
though this transition is possible, if careful cross-tapering is 
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tients are given a typical neuroleptic drug, motor side effects 
of the latter may be more intense for a while than ever expe-
rienced previously with such drugs [8,27,84]. 
  Apart from the pattern described by Chouinard and col-
leagues, how is one to understand the two other patterns of 
events, after withdrawal, respectively of standard neuroleptic 
drugs, and of clozapine? For clozapine withdrawal, the evi-
dence provides many hints of compensatory change in recep-
tor numbers (sub- or supersensitivity), leading transiently to 
severe pathology. Which are the relevant receptors? Why is 
this pattern not seen with typical neuroleptics, or other atypi-
cal drugs? 
  Fig. (1) is a schematic depiction of events occurring with 
standard neuroleptic drugs (left), and for clozapine (right). 
For each class of drug, there are three phases (columns), ini-
tial acute treatment, chronic treatment (months or years), and 
then  sudden  withdrawal.  Six  variables  (rows)  are  repre-
sented: (i) the number of D2 receptors (located on choliner-
gic interneurones); (ii) the release of ACh from these neu-
rones (increased, when D2 receptors are blocked by standard 
antipsychotic drugs); (iii) the number of muscarinic M4 re-
ceptors  (located  on  the  medium  spiny  neurones);  (iv)  the 
intracellular synthesis of cAMP, which is reduced if the M4 
receptors are activated by any available extracellular ACh or 
agonist drug; (v) the M1 receptors located on the same neu-
rones; (vi) motor side effects resulting from over-stimulation 
of M1 receptors. 
  Consider  first  the  situation  with  standard  neuroleptic 
drugs:  Their  acute  effect  is  to  increase  ACh  release;  and 
then, as one enters the phase of chronic administration, the 
D2  receptors  proliferate,  as  do  any  receptors  which  are 
chronically  blocked.  As  a  result  of  this  compensatory 
change,  the  ability  of  available  extracellular  dopamine  to 
reduce ACh release is gradually restored, so that ACh release 
falls towards, and possibly even reaches its previous baseline 
level. At the same time, the phase of increased ACh release 
leads at first to excess stimulation of M1 and M4 receptors. 
The  numbers  of  both  these  receptor  types  then  falls  over 
time, as compensation for over-stimulation. (In Parkinson’s 
disease, where, according to theory, ACh release should also 
be increased, a similar reduction of M1 receptor numbers has 
been  empirically  demonstrated  [53]).  Eventually,  as  ACh 
release falls back towards normal, the numbers of M1 and 
M4  receptors  climb  back  towards  (or  even  reach)  normal 
levels. In the medium spiny neurones, cAMP formation ini-
tially  falls  and  parkinsonian  motor  symptoms  initially  ap-
pear, but then there is later desensitisation to this effect of 
increased ACh release. Later still, as ACh falls back to nor-
mal  levels,  resensitisation  gradually  occurs  in  the  medium 
spiny neurones, so that the initial decrease in cAMP forma-
tion tends to be restored towards (or even reaches) baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Events prior to and on discontinuation of chronic regimes of classical (D2-blocking) antipsychotic drugs, and clozapine. See 
text. 1: On withdrawal of chronic regimes of D2-blocking drugs, release of cAMP production, and psychotic rebound, if it occurs, is not se-
vere. 2: On withdrawal of clozapine, cAMP production increases with little to hold it back (in the short term), and psychotic rebound may be 
severe. 3: Likewise, on withdrawal of clozapine, substitution by D2-blocking drugs (dashed trace) may produce motor side effects more se-
vere than such drugs would produce prior to clozapine treatment. Mechanisms of Action of Antipsychotic Drugs  Current Neuropharmacology, 2009, Vol. 7, No. 4    317 
levels, and the initial intensity of motor side effects declines. 
At the time of drug withdrawal, any persisting acceleration 
of ACh release is abruptly terminated, so that ACh release 
may  fall  suddenly,  cAMP  synthesis  in  principal  neurones 
abruptly rises, and any remaining motor side effects abate. 
However,  since  the  number  of  M4  receptors  has  returned 
towards (or even reaches) a normal level, and there is still 
adequate ACh release, there are still factors limiting produc-
tion of cAMP. Hence, psychotic rebound, if it occurs is not 
very florid. 
  Now  consider  the  alternative  scenario,  with  clozapine 
withdrawal. It is assumed here that at optimal doses, the ef-
fects are exerted mainly at M4 receptors (as agonists) and 
M1 receptors (as antagonists), but not at D2 or D1 receptors 
(for which clozapine has lower affinity). Therefore, in Fig. 
(1) the upper two variables (D2 receptor numbers, and ACh 
release) are assumed to stay unchanged. At the M4 receptors, 
chronic activation by clozapine will lead to progressive de-
sensitisation  (reduction  in  receptor  numbers),  with  no  ten-
dency to normalize, even with prolonged treatment. Produc-
tion of cAMP, initially sharply reduced will tend to normal-
ize as the receptor numbers drop. The M1 receptors will pro-
liferate, again with no tendency to normalize over time. At 
the time of withdrawal of clozapine, sufficient endogenous 
ACh may be available to act on the  M4 receptors, but its 
ability to reduce cAMP formation is far below normal, be-
cause of the desensitisation of the M4 receptors. The result is 
that there is little to check production of cAMP, which rises 
suddenly,  dramatically,  and  beyond  the  level  found  with 
withdrawal  of  standard  drugs.  The  result  is  dramatic  and 
florid, a sudden-onset, rebound psychosis, requiring doses of 
clozapine larger than originally needed before it is brought 
under  control.  Even  standard  neuroleptic  drugs  will  have 
reduced ability to alleviate psychosis, because their actions 
depend on adequate sensitivity of M4 receptors. At the same 
time, due to proliferation of previously-blocked M1 recep-
tors, any typical neuroleptic, used to protect against rebound 
psychosis, acting by acceleration of ACh release, will pro-
duce motor side effects more severe than produced by these 
drugs prior to the use of clozapine. The striking finding that, 
on clozapine withdrawal both psychosis and vulnerability to 
motor side  effects  are more severe than prior to treatment 
with this drug indicates that, unlike endogenous ACh, clo-
zapine is an agonist at only one receptor (M4), but an an-
tagonist at the other (M1). However, the receptor changes are 
transient, and the severe effects of both down-regulation at 
M4  receptors,  and  up-regulation  of  M1  receptors  decline 
over time. 
  Why are such “rebound” psychotic reactions more severe 
in previously neuroleptic-responsive patients, than in those 
who are refractory to such drugs? Probably, because, in the 
former cases cholinergic interneurones are present in larger 
numbers.  Therefore,  during  chronic  clozapine  administra-
tion, the M4 receptors are activated not only by clozapine, 
but also to a significant extent by endogenous ACh. Over the 
period of chronic administration, the resultant desensitisation 
of these receptors is then more profound than in refractory 
patients. 
  Why  are  drugs  with  anticholinergic  potency  helpful  as 
protection against these rebound effects? This is a difficult 
question to answer. Antagonists at M1 receptors would be 
expected to attenuate motor side effects, but antagonists at 
M4 receptors should release cAMP synthesis from its previ-
ous suppression, and therefore should accentuate, rather than 
protect against the “rebound” psychosis. One possible expla-
nation of this may be that some of the commonly-used “anti-
cholinergic” agents (including trihexyphenidyl, benztropine, 
benperiden, procyclidine, pirenzepine and diphenhydramine), 
may block actions of ACh at only some of the muscarinic 
receptors, especially the M1 type, while acting as agonists at 
the critical M4 receptors. Available data [9] show that anti-
cholinergic agents commonly used to reduce motor side ef-
fects of antipsychotic drugs have roughly similar affinities 
for M1 and M4 muscarinic receptors, but there are no data to 
prove the specific point, that any of these act as antagonists, 
rather than agonists at M4 receptors. If any such drugs are 
agonists at M4 receptors, they might even have a therapeutic 
role by themselves. 
2. ARE THERE ANY OTHER DRUGS IN REGULAR 
USE, WITH PROPERTIES LIKE CLOZAPINE? 
  Clozapine is a far from ideal drug. Apart from its psy-
chopharmacology, and the risk of transient rebound reactions 
on  its  withdrawal,  it  has  a  tendency  sometimes  to  cause 
agranulocytosis,  which,  if  detected  requires  it  to  be  with-
drawn.  This  is  a  serious  matter,  since  no  other  drug  has 
proven efficacy equal to clozapine in neuroleptic-refractory 
psychotic illnesses.  Do any other currently-available drugs 
have a profile similar to clozapine, which was never properly 
defined? 
  There are nine criteria by which such an agent might be 
recognised, based partly on direct empirical evidence, partly 
on theory developed in this paper (all discussed as principles, 
in PART I, and the preceding section of PART II of this pa-
per):  
(i)  The agent should be antipsychotic with low incidence 
of acute motor side effects. 
(ii)  It need not lead to elevation of blood prolactin levels 
(an effect  attributed  to D2 blockade [49]). Failure  to 
meet this criterion does not disprove the thesis that a 
drug has clozapine-like clinical properties, because af-
finity for M4 and D2 receptors may be very similar.  
(iii)  It  should  be  effective  in  refractory  psychosis.  When 
evidence  is  inconclusive,  less  rigorous  early  studies 
may point to the need for more critical tests. 
(iv)  Some agents fitting criterion [i] owe this to the combi-
nation of dopamine D2 and 5HT2a antagonism, with-
out fulfilling criterion [iii]. When an agent fits criterion 
[i] without having the “SDA” profile, its status is en-
hanced as a candidate “clozapine-like” drug. 
(v)  The agent should have affinities for dopamine D1 or 
muscarinic M4 receptors equal to, or higher than that 
for dopamine D2 receptors.  
(vi)  If an agent does have high relative affinity for M4 re-
ceptors, it should act at such receptors as an agonist or 
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(vii)  When used in doses effective for antipsychotic therapy, 
it should have low (>60%) occupancy of dopamine D2 
receptors. A specific upper limit cannot be stated, be-
cause  different  drugs  vary  in  their  relatives  affinities 
for D1 or M4 receptors, compared to D2 receptors. 
(viii) In advanced Parkinson’s disease, a potential clozapine-
like  agent  should  alleviate  drug-induced  psychosis, 
without exacerbating parkinsonian symptoms. 
(ix)  On sudden discontinuation, immediate and severe (but 
transient)  psychotic  relapse  should  be  more  common 
than  the  relapse  rate  seen  with  typical  neuroleptic 
drugs,  or  the  better-known  “SDA”  atypical  antipsy-
chotic drugs fulfilling none of criteria [iii] and [v-viii]. 
This  is  an  important  criterion,  but  a  difficult  one  on 
which to obtain decisive evidence: Withdrawal even of 
classical  neuroleptic  drugs  may  sometimes  lead  to 
rapid psychotic relapse (either due to supersensitivity 
psychosis, or occasionally, even without this complica-
tion). On the other hand, even with an ideal clozapine-
like drug, relapse on withdrawal need not be immedi-
ate: From the theory developed above, increased cAMP 
production on withdrawal of an M4 agonist is condi-
tional on activation by some other agent, especially ex-
cessive dopamine release, acting at D1 receptors. If do-
pamine release is not excessive, withdrawal-emergent 
psychosis  may  not  occur  even  with  clozapine.  Care-
fully controlled studies of matched groups comparing 
withdrawal syndromes with different drugs are needed 
to provide firm evidence on this point. 
  Given this list of criteria, four drugs, apart from clozap-
ine are of interest, dealt with in turn below, and summarized 
in Table 1. It is not intended to establish a watertight case 
that any of these agents is a clozapine-like drug, but rather to 
indicate  that,  in  absence  of  conclusive  evidence,  there  is 
enough suggestive evidence to warrant more rigorous test-
ing. Criteria [ii], [iv] and [vii] are ones which suggest clo-
zapine-like properties, if fulfilled, but do not exclude such 
properties, if they are not met. For instance clozapine itself 
fails to meet criterion (iv): It does have high 5HT2a/D2 af-
finity ratio. 
  Fluperlapine was developed by Sandoz, to replace clo-
zapine, after that drug was withdrawn in the 1970s. It has 
higher affinity for D1 than for D2 receptors, and even higher 
affinity for M4 receptors (PART I, Table 1). The data are not 
clear however, since in a functional assay, its potency as an 
M4  agonist,  in  reducing  cAMP  formation  (stimulated  by 
forskolin) was much lower. Like clozapine, it has high rela-
tive affinity for 5HT2a receptors [83]. It is an effective anti- 
psychotic  agent  with  low  incidence  of  motor  side  effects 
[28,37,72,129,130],  and  is  also  effective  against  drug-
induced psychosis in Parkinson’s disease [62,105]. Its effi-
cacy in refractory psychosis is not proven, but is suggested 
by one clinical trial [37], whose patient group included ten 
patients in this class, and for which overall results were “bet-
ter than previous drugs” in 60% of patients (similar to clo-
zapine). There are no published data on its D2 occupancy at 
therapeutic doses, nor on the likelihood of rapid-onset with-
drawal psychosis for this drug. This agent was not widely 
marketed, because, like clozapine, it had an associated risk 
of agranulocytosis. 
  Thioridazine was developed in the late 1950s, and was 
the subject of many clinical studies in the period 1959-1962. 
It has affinity for M4 receptors similar to that for D2 recep-
tors (PART I, Table 1), and a little higher than for D1 recep-
tors. However, the form usually available is a racemic mix-
ture, one of the enantiomers having higher affinity for D1 
than for D2 receptors. No data are available on the affinity of 
the different enantiomers for the M4 receptor. In a functional 
Table 1.  Potential Clozapine-like Drugs: Synopsis 
Drug  
Criterion 
Clozapine  Fluperlapine  Thioridazine 
or One of its 
Isomers 
Mesoridazine 
or One of its 
Isomers 
Quetiapine 
Antipsychotic without motor side effects    [a]    [b]   
No elevation of blood prolactin    [c]  [c]  ?  [d] 
Effective in refractory 
 psychosis 
  ?()[e]  ?()[f]  ?()[b]  ?()[g] 
Fits ‘SDA’ profile  Yes  Yes [h]  No [h]  ?  ?Yes[i] 
High relative M4 affinity    [j]  [j]  ?[j]  [j] 
M4 agonist    ?[j]  ?[see text]  ?  [j] 
Antipsychotic with low D2 occupancy    ?  ?  ?  [Sect 3] 
Effective in Parkinson’s L-DOPA psychosis     [k]  ?[l]  ?  [m] 
Risk of rapid rebound psychosis    ?  ?[n]  ?  [o] 
Notes: :criterion definitely fulfilled; :criterion not fulfilled; ?():suggestive evidence that criterion is fulfilled. 
Sources:.a: [28,37,72,129,130]; b: [43,124]; c: [32]; d: [19,49,56]; e: [37]; f: [17,51,67,124]; g: [18,79,116]; h: [83]; i: [12,100,134]; j: see Table 1 (PART I); k: [62,105]: l: [55]; m: 
[26,29,35,40,54,60,92]; n: [7,23,30,68,111]; o: [36]. Mechanisms of Action of Antipsychotic Drugs  Current Neuropharmacology, 2009, Vol. 7, No. 4    319 
assay  it  is  an  effective  inhibitor  of  forskolin-stimulated 
cAMP formation, but this effect is not blocked by the non-
selective muscarinic  antagonist atropine (unlike the effects 
of clozapine, fluperlapine or olanzapine), so its status as an 
M4 agonist is uncertain [132]. It is not classed as atypical in 
terms of its relative affinities for 5HT2a and D2 receptors 
[83]. Its D2 occupancy in humans, when given in therapeutic 
doses  is  said  to  be  similar  to  that  for  typical  neuroleptic 
drugs, and not unusually low (as with clozapine). However, 
this statement is based on only two subjects [34], for whom 
the dose was quite large (300 and 400 mg/day respectively) 
and for whom it was unclear how close their dose was to the 
minimum effective dose. In any case, since its affinities for 
the D1 and D2 receptors are not very different, and would 
depend on the proportion of the two optical isomers in the 
preparation  used,  expectation  of  major  differences  from 
standard neuroleptic drugs in occupancy at therapeutic doses 
is uncertain. 
  Two points suggest that it deserves more serious consid-
eration  as  an  equivalent  to  clozapine,  but  safer.  First, a l-
though  it  has  never  been  rigorously  tested  in  neuroleptic-
refractory patients, several older less rigorous studies suggest 
that it might be effective in such cases: One early study [51] 
found it to be effective  in nine out of 28 cases “who had 
proved refractory to less radical treatment with other tran-
quillising  drugs”.  Another  [67]  compared  it  with  several 
classical neuroleptics. In a trial over 24 weeks, the  “drop-
out” rate due to lack of improvement or deterioration was 
12-15%  for  the  drugs  chlorpromazine,  chlorprothixene, 
fluphenazine,  and  triflupromazine,  but  was  only  4.7%  for 
thioridazine  (based,  for  each  drug,  on  ~85  patients).  This 
suggests that thioridazine was effective in some cases refrac-
tory to treatment with the other drugs. In another study, good 
responses  were  described  to  thioridazine  in  seven  patients 
refractory  to  chlorpromazine,  haloperidol,  or  thiothixene 
[124]. In a fixed-dose trial of thioridazine in 53 patients [17], 
all patients eventually improved, and all but three improved 
quite  substantially,  being  discharged  either  “markedly  im-
proved” (77%) or with “symptoms in remission” (15%). This 
is a possible indication that it is effective even in refractory 
patients. However, two studies [43,48] failed to find thiori-
dazine superior to standard drugs in refractory patients. Thi-
oridazine has also been recommended for treatment of drug-
induced psychosis in Parkinson’s disease [55]. If it could be 
proven that thioridazine was effective treatment in refractory 
psychosis, it would be a viable alternative to clozapine, since 
the  risk  of  cardiac  complications,  though  higher  than  for 
most antipsychotic drugs, is still quite low [99]. 
  The second point of possible similarity to clozapine is the 
pattern of events occurring after sudden withdrawal, in pa-
tients receiving thioridazine for some time. The evidence on 
this is scanty and imprecise. It is certainly true that discon-
tinuation of thioridazine can sometimes be achieved without 
major problems [1,10,68], and withdrawal-emergent difficul-
ties  do  not  necessarily  amount  to  psychotic  exacerbation 
[63]. Sudden withdrawal of thioridazine is usually initiated 
by patients, so precise documentation is less likely than for 
clozapine, where closer scrutiny is now common (due to the 
risk of agranulocytosis). For sudden-onset psychotic relapse, 
there are usually more pressing concerns, and so this topic 
has not been the object of systematic study. In the UK, thio- 
ridazine was widely prescribed, especially for intellectually-
disabled persons in institutional care, but was withdrawn in 
2002, following concern about possible effects on the ECG. 
When  used  in  intellectually-disabled  persons,  diagnosis  is 
likely  to  be  inexact,  with  much  heterogeneity  within  the 
groups studied. Communication difficulties may also prevent 
exact recognition of psychotic states on withdrawal. How-
ever,  the  fact  of  withdrawal-emergent  problems  is  more 
likely  to  be  documented  in  such  persons.  Given  these  
caveats, it is reported that, after long-term thioridazine treat-
ment, behavioural disturbance, or extreme anxiety may occur 
on discontinuation [7,23,111], sometimes leading to hospi-
talisation under section [30]. These difficulties include some 
cases of definite rapid psychotic relapse [68]. Decompensa-
tion could not be corrected by standard doses of other neuro-
leptic drugs [23], a pattern similar to that reported with clo-
zapine (see above). The present author, when much younger, 
had a serious psychiatric illness, was prescribed thioridazine, 
which was taken in small doses for nearly forty years (1968-
2007; ~300 mg/d for the first two years; but mainly 50 mg/d 
since then). On three occasions between 1969 and 1980 he 
tried, very carefully, to withdraw from this medication. On 
all three attempts he was prevented from this, within days of 
complete cessation of the medication by resurgence of psy-
chotic symptoms, leading on one occasion (in 1973) to re-
admission  to hospital,  an account of which has been pub-
lished [88]. An enquiry made to the UK Pharmacovigilance 
service  (e-mail  address:  Pharmacovigilance@mhra.gsi.gov. 
uk) revealed (26.9.08) 17 reports of adverse reaction on dis-
continuation  of  thioridazine  in  the  “CNS/Psychiatry”  area. 
These included individual cases described as: “psychomotor 
hyperactivity”, “abnormal behaviour”, “aggression”, “agita-
tion”, “anger”, “anxiety”, “hallucinations, visual”, “restless-
ness”,  “intentional  self-injury”,  “mental  status  changes”, 
“suicidal  behaviour”,  “suicidal  ideation”  and  “suicide  at-
tempt”. Most of these descriptions are not precise enough to 
identify  psychotic  decompensation,  perhaps  because  they 
were documented in intellectually-impaired persons. Never-
theless, they do constitute evidence for a syndrome of ab-
normal  behavioural  or  psychological  activation  on  discon-
tinuation of this drug. 
  Mesoridazine is a metabolite of thioridazine. In addition 
to the site of asymmetry possessed by the thioridazine mole-
cule,  another  such  site  is  introduced  during  its  formation. 
Thus there are four optical isomers to take into considera-
tion. In its racemic form, affinity for M1 and M4 receptors is 
a  little  lower  than  for  D2  receptors,  but  it  is  not  known 
whether it  is an  agonist or  antagonist. Data for individual 
isomers on affinity are available for the dopamine D1 and 
D2 receptors, but not for the muscarinic M1 or M4 receptors 
(PART 1, Table 1). It is thus possible that specific enanti-
omers may have affinity for M1 or M4 receptors equal to or 
greater  than  those  for  dopamine  receptors.  It  is  not  clear 
whether it fits the “SDA” profile. Clinically, in its racemic 
form, two studies show it to be antipsychotic without causing 
motor side effects [43,124], these two also providing tenta-
tive evidence for its efficacy in refractory patients. Nothing 
is known of its occupancy of D2 dopamine receptors when 
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psychoses in Parkinson’s disease, or the risk of rapid-onset 
withdrawal-emergent psychosis. 
  Quetiapine is a recently-developed drug, but has proper-
ties  distinct  from  most  atypical  antipsychotics  with  the 
“SDA” profile. Its status is rather enigmatic. It probably has 
low  relative  affinity  for  both  D1  dopamine  and  M4  mus-
carinic receptors compared to dopamine D2 receptors (PART 
I, Table 1), and, whatever its affinity, it appears not to act as 
an agonist at M4 receptors. It has affinity for 5HT2a recep-
tors similar to that for D2 receptors [17,126,134], and there-
fore could fit the “SDA” profile. Nevertheless, it has some 
clozapine-like  clinical  properties,  unlike  those  of  other 
“SDA” atypical antipsychotic agents. In single-case studies 
of psychosis unresponsive to other treatments (sometimes in 
combination  with  other  atypicals,  or  at  high-doses),  it  has 
been reported to be effective [11,16,96], and in some con-
trolled  studies  [102]  it  has  shown  favourable  responses  in 
refractory  patients  (though  not  superior  to  other  atypical 
drugs).  However,  in  three  controlled  studies,  two  of  them 
large trials, it was not superior to other atypicals [18,79,116]. 
It is useful in drug-induced psychoses of Parkinson’s disease 
[26,35]  (using  relatively  low  doses,  as  also  recommended 
with clozapine), and, for this, is preferred to other atypicals 
[40]. In group comparisons with clozapine in such patients 
clozapine is found to be equal [92] or superior [29,60] to 
quetiapine. Nevertheless, there are hints that different groups 
of patients are helped by these two drugs: Switch from clo-
zapine to quetiapine may be difficult [35], but in some cases 
proves valuable when clozapine at maximum tolerated doses 
is ineffective [54]. It has antipsychotic potency at low levels 
of D2 occupancy [47,58,65,119]. It is associated with a sub-
stantial risk of rapid withdrawal-emergent psychotic rebound 
[36,73]. In a single case study [126] rapid transfer from clo-
zapine to quetiapine was not accompanied by any rebound, 
suggesting cross-sensitisation between the two drugs. 
  Quetiapine is difficult to accommodate within the theory 
presented in this paper, because some of the criteria derived 
from that theory (antipsychotic actions at low D2 occupancy, 
relative  lack  of  motor  side  effects,  effectiveness  in  drug-
induced psychoses of Parkinson’s disease, rapid-onset with-
drawal-emergent  psychoses,  and  possibly  effectiveness  in 
some  refractory  psychoses)  are  met,  while  other  essential 
criteria (lack of high relative affinity for either the D1 or M4 
receptors) are not. It is possible that some of the evidence 
published so far, or the reasoning behind the theory are in-
correct. A more interesting possibility is that there are causes 
of  neuroleptic-refractory  psychoses  with  bases  other  than 
those discussed here (i.e. loss of striatal cholinergic interneu-
rones),  these  causes  being  rectified  by  quetiapine  but  not 
clozapine. This possibility is made more plausible by the fact 
that some of the patients refractory to standard neuroleptics 
are  also refractory  to clozapine. Such patients  may yet be 
responsive to quetiapine. The less-certain basic and clinical 
evidence  about  quetiapine  needs  confirmation  before  this 
possibility becomes more definite. 
3.  DEFINITION  IN  PRACTICE  OF  INDIVIDUAL 
SENSITIVITY TO ANTIPSYCHOTIC DRUGS 
  Is there any way to define the range of individual sensi-
tivity  to  antipsychotic  drugs  in  acute  treatment,  based  on 
therapeutic response, rather than on the subtle motor changes 
underlying Haase’s neuroleptic threshold? Is there a practi-
cal way of determining individual sensitivity, to guide dos-
age used? Any answers to such questions require documenta-
tion  of  individual  rather  than  group-averaged  clinical  re-
sponse. It is then better to take plasma concentration rather 
than  dose  as  the  independent  variable,  this  measure  being 
closer to clinical response. A number of papers relate clinical 
response to plasma level of various antipsychotic drugs, and 
give  values  of  both  variables  for  individual  patients.  The 
drug haloperidol is used in the largest number of such stud-
ies, this drug having no active metabolites. For oral halop-
eridol, the twenty such studies (Table 2) give data on 558 
patients, recently admitted to hospital after acute exacerba-
tions,  or  studied  as  chronic  in-patients  after  a  placebo 
“washout” period. The studies use several different clinical 
rating scales, and some use “difference scores” others using 
“percent change”. To give equivalence of clinical response 
measures  across  studies,  the  “change”  measures  for  each 
study are transformed to “z-scores” (change score, as differ-
ence  or  percent,  divided  by  the  standard  deviation  for  the 
change score in that study). (In principle, additional studies 
using other drugs could be plotted on the same graph, but 
this would involve the difficult task of matching “clinically 
equivalent plasma levels” between drugs.) For haloperidol, 
the resulting plot, with the horizontal axis (plasma level of 
haloperidol, in ng/ml) on a logarithmic scale is presented in 
Fig. (2A). Fig. (2B) presents an analysis of the same data, 
showing means and SDs of the z-scores (dividing the total 
number of 558 patients, ranked according to plasma level, 
into  46  subgroups  of  9-36  patients  each,  for  overlapping 
ranges of plasma levels (see legend to Fig. 2B for details). 
Several points are clear from Fig. 2A: 
(i)  There is great spread of measured clinical response at 
any  plasma  level,  with  no  sign  of  bimodality  of  re-
sponse  (as  might  be  expected  if  “responders”  were 
separate from “non-responders”). 
(ii)  Given such wide variability of response, there is also a 
graded increase with plasma  level, in  the  “maximum 
possible” response (seen in the “best responders”). This 
occurs for plasma levels between about 2 ng/ml and 7 
ng/ml. Therefore, at least for these “best responders”, 
an S-shaped dose-response curve appears to fit the rela-
tionship with plasma level, with ranges at low and high 
values of plasma concentration where clinical response 
does not improve as the plasma level increases, and an 
intermediate range with progressive increase in clinical 
response with plasma level increase. At least for these 
“most sensitive” patients, the clinical response to anti-
psychotic drugs appears not to be “all-or-none” (a “step-
function” of dose) as suggested by Haase’s “neurolep-
tic  threshold”  concept.  The  relation  between  plasma 
level and clinical response is shown more explicitly in 
Fig. 2B. Here the fraction of patients who fail to re-
spond is high (~75%) at the lowest plasma levels, and 
falls between plasma levels of 2 to 7 ng/ml, while at the 
same  time,  the  extent  of  average  clinical  response 
climbs to z>2. For 246 patients with “optimal” halop-
eridol  plasma  levels  between  6.5-14.5  ng/ml,  only 
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Table 2.  Studies Giving Individual Data on Plasma Levels and Clinical Response, for Haloperidol in Treatment of Acute Psychosis 
Authors, Chrono-
logical Order 
Trial Duration  Number of 
Subjects 
Patients  Clinical Scale, and Measure  Comments 
a  3-12 wk  17  Acute exac  BPRS total improvement 
difference score 
16 out-patients, 1 in-patient 
b  4 wk  16  Acute exac  BPRS total improvement 
difference score 
 
c  14 d  14  Acute exac  NHSI; % improvement   
d  28 d  10  Acute exac  AMS Global improvement 
difference score 
 
e  2 wk  14  Acute exac  NHSI; % improvement   
f  20 d  36  Acute exac  BPRS total improvement 
difference score 
18: manic psychosis 
18 schizophrenic psychosis 
g  24 d; 1-3 wk 
washout 
27  Chronic in-
patients 
BPRS-psychosis;  
% improvement 
Included: those showing exac during 
washout; Excluded: those known as 
neuroleptic-refractory 
h  42 d  20  Acute exac  BPRS total improvement 
difference score 
 
i  42 d; 6 wk 
washout 
19  Chronic 
in-patients 
BPRS-psychosis;  
% improvement 
 
j  42 d; > 1 wk 
washout 
44  Chronic in-
patient 
CGI Global improvement  
difference score 
 
k  28 d  13  Acute exac  BPRS-psychosis;  
% improvement 
 
l  29 d  16  Acute exac  BPRS-psychosis;  
% improvement 
 
m  6 wk; >4 wk 
washout 
30  Chronic in-
patients 
BPRS-psychosis;  
% improvement 
 
n  21 d  28  Acute exac  BPRS-psychosis;  
% improvement 
None known to be neuroleptic refrac-
tory 
o  2 wk  29  Acute exac  BPRS-psychosis;  
% improvement 
 
p  28 d  26  Acute exac  BPRS-psychosis;  
% improvement 
33% of subj dropped out by 28d; no 
evidence that this biased the results 
q  21 d  20  Acute exac  BPRS-psychosis;  
% improvement 
 
r  3 wk; 1 wk 
washout 
54  Acute exac  BPRS-psychosis;  
% improvement 
 
s  28 d  68  Acute exac  BPRS psychosis improvement 
difference score 
 
t  21 d  57  Acute exac  BPRS-psychosis;  
% improvement 
 
References: a: [71]; b: [33]; c: [77]; d: [128]; e: [45]; f: [4]; g: [110]; h: [70]; i: [6]; j: [97]; k: [109]; l: [93]; m: [59]; n: [103]; o: [57]; p: [114]; q; [95]; r: [125]; s: [121]; t: [120]. 322    Current Neuropharmacology, 2009, Vol. 7, No. 4  R. Miller 
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Fig. (2). A (Upper): Plot, for 558 individual psychotic patients treated with haloperidol, of clinical response (expressed as z-score, on vertical 
axis) versus plasma concentration (ng/ml, log scale, on horizontal axis). See Table II for details of studies from which data were obtained. B 
(Lower): The same data as in A, with patients divided into 46 overlapping subgroups according to ranges of plasma haloperidol levels. For 
each subgroup, the graph shows mean clinical response (filled circles) ± SD, and the proportion of patients who failed to give greater-than-
placebo clinical response (z≥1) (filled squares). (Left-most subgroup: n=9; subgroups with plasma levels between 7 and 14.5 ng/ml: n=36; all 
other subgroups: n=18; each patient represented in each of two adjacent groups). 
 
  Fig.  (2B)  gives  an  indication  that  the  most  sensitive 
patients  may  begin  to  show  a  clinical  response  for 
plasma levels as low as 1.5 ng/ml, while the least sensi-
tive ones may not show a response until the level ex-
ceeds 7-10 ng/ml. The lower and upper “tails” in the 
distribution  of  individual  sensitivity  are  defined  by 
very few patients, so the exact points of maximum and 
minimum  sensitivity  are  not  defined  precisely.  It  is 
likely that the complete range of individual sensitivity 
from  most  to  least  sensitive  patients  spans  at  least  a 
ten-fold range of plasma concentrations, a conclusion 
in agreement with that reached from estimate of “neu-
roleptic  threshold”,  or  minimum  proven  maintenance 
doses (PART I, Sect. 5). 
(iii)  In  previous  attempts  to  establish  a  relation  between 
dose or plasma level and clinical response to antipsy-
chotic drugs, there have been hints that, at high doses 
or plasma  levels, the clinical response is less  than at 
moderate doses. In other words, there is a “therapeutic 
window” for dose or plasma levels [25,44,64,112,125]. 
This concept has been discussed in earlier publications 
by the present author [86,87]. In individual studies, the 
number of data points is too small assess it critically. 
Fig.  (2)  permits  it  to  be  tested  more  rigorously.  For 
plasma levels above 14.5 ng/ml, averaged clinical re-
sponse falls to a mean response (z-score) of 1.4±1.03, a 
value different from that in the optimal range of plasma 
levels  to  a  high  degree  of  statistical  significance 
(p>0.0001). The difference between optimal and supra-
optimal ranges for plasma concentration has also been 
found to a statistically significant level within a single 
study  [22]:  Patients  with  acute  exacerbations,  and 
haloperidol plasma levels >25ng/ml showed less clini-
cal response, and took longer to reach a criterion levels 
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though, at such high plasma levels, motor side effects 
did not differ between groups. 
  Several recent studies of dose-response relationships for 
antipsychotic  drugs  [22,52,69,78]  have  excluded  from  the 
analysis patients who fail to respond beyond a criterion level, 
even with large doses, and long trial durations. For such pa-
tients,  the  clinical  response  should  not  exceed  “placebo” 
effects. How much of the clinical response can be attributed 
to  “placebo  effects”?  This  issue  has  been  discussed  in  a 
meta-analysis [127]. Placebo effects (measured using BPRS 
total scores) ranged from effect sizes of +0.29 (deterioration) 
to  -0.76  (improvement),  with  a  mean  of  -0.13.  The  effect 
tended to be larger (more negative) for short duration trials, 
perhaps due to non-specific factors stabilizing the patients’ 
state, as a result of hospitalisation. Specifically, the placebo 
improvement fell by ~1 BPRS unit per week of the trial. This 
is a small proportion of the improvement over 4-6 weeks, 
and is therefore not a major confound for group averages. 
This paper also gives SDs of change scores for each study, 
from which, for each study one can compute the 1SD range 
for individuals within that study. For 17 studies, comparing 
810 patients in trials lasting 3-8 weeks, the weighted mean 
SD for the placebo groups was 14.78 BPRS units. From the 
20 studies used to plot Fig. 2, three [4,70,71] give individual 
data (in total for 73 subjects) on “BPRS total” change scores, 
expressed as difference rather than percentage change. From 
this, the SD for the change score is 13.59 BPRS unit, quite 
similar to the weighted mean SD for the placebo groups in 
the  meta-analysis  of  placebo  effects  [127].  Therefore,  in 
Figs. (2A) and (2B), a horizontal dashed line is drawn at z=1, 
to  represent  the  approximate  limit  of  “placebo  response”. 
Responses greater than this are then likely to be drug effects. 
Using this criterion, the fraction of patients who fail to re-
spond  above  z=1  rises  (Fig.  2B;  square  symbols),  from 
25.5%  in  the  optimal  range  to  37.58%  for  plasma  levels 
above 14.5 ng/ml (0.05>p>0.01). If non-responding patients 
(with z<1) are  excluded from the analysis,  the clinical re-
sponse (expressed as a z-score) of the remaining patients is 
again  lower  in  the  high  than  in  the  optimal  plasma  level 
range (2.04±0.73 versus 2.25±0.85), although to a lesser de-
gree of significance (p=0.035) than for the total number of 
patients in each group. 
  Several explanations can be offered for the apparent de-
cline in clinical response at high plasma levels. It might be 
suggested that the decline is an artefact arising because the 
rating scales used change when high doses are used, for in-
stance because the total symptom picture includes a higher 
proportion of negative symptomatology. It is  also possible 
that  improvement  of  psychotic  symptoms  is  not  seen  so 
clearly in patients with prominent motor side effects. This is 
compatible with  the analysis shown in Fig. 2B: Using the 
formula of Fitzgerald and co-workers [38], one can infer that 
an approximate doubling of plasma levels would be needed 
to go from the 65% occupancy (said to be the threshold for 
therapeutic  effects)  to  that  producing  80%  occupancy 
(threshold  for  major  motor  side  effects).  In  Fig.  2B,  the 
plasma  concentrations  over  which  optimal  responses  are 
obtained also extends over a roughly two-fold range. A fur-
ther  explanation  of  the  decline  in  response  at  high  doses, 
based  on  theory  similar  to  that  used  here,  was  offered  by 
Miller [85,86]. Just as acquisition of some symptoms, such 
as delusional beliefs, requires modifiability of beliefs (equi-
valent at the biological level to dopamine-mediated synaptic 
change), so also does recovery from the same symptoms. At 
the  highest  plasma  levels  and  highest  D2  receptor  occu-
pancy, ACh release may be so high that cAMP formation is 
reduced so far that such modification is no longer possible. 
To  evaluate  this  idea  requires  detailed  psychopathological 
study in the recovery phase, to uncover exactly which symp-
toms fail to respond at high doses. 
  Even  after  excluding  placebo  responses,  there  is  great 
variability in measured clinical response. This is due to sev-
eral factors: Two of these are: (i) imprecision in the rating 
scales used (strictly “uncertainty” rather than “variance” in 
clinical  response);  (ii)  differences  between  patients  in  the 
completeness with which symptoms can be eliminated, due 
to a variety of individual characteristics, such as personality 
variables  independent  of  their  illness,  persisting  effects  of 
past episodes etc. These factors would lead to vertical spread 
of individual data on a hypothetical S-shaped dose-response 
curve. However, bearing in mind the possibility that there is 
wide individual variation in sensitivity to the drug, the distri-
bution of clinical responses across patients may reflect su-
perimposition of a number of “vertically blurred” S-shaped 
curves, displaced to varying degrees in the horizontal axis 
(Fig. 3, left). For the sloping part of each curve, such hori-
zontal  displacement  would  contribute,  as  a  third  variable, 
determining  the  apparent  vertical  spread  of  points.  If  this 
were the case, and individual variation in sensitivity is cor-
rectly assessed in Haase’s handwriting test, or similar sensi-
tive measures of motor changes, a prediction can be made: If 
the clinical response in each patient were corrected for dif-
ferences in neuroleptic threshold, rather than being expressed 
as  a  function  of  plasma  levels,  all  the  “blurred”  S-shaped 
curves would be collapsed to the same position in the hori-
zontal axis; and then, the vertical spread of the clinical re-
sponse measures, after excluding “placebo effects” would be 
reduced. A bimodal spread of clinical responses in the total 
population might then appear, with clear separation of “re-
sponders” from “non-responders” (Fig. 3, right). 
  In  practice,  tests  such  as  the  handwriting  method  of 
Haase  cannot  be  used  reliably  unless  they  are  quantified. 
Measures of the area of a standardized piece of text written 
by each patient have been found to correlate across patients 
with  occupancy  for  dopamine  D2  receptors  [66].  A  more 
sophisticated quantified version of the handwriting test has 
been developed [13], based on kinematic analysis of move-
ment  velocity,  and  its  scaling  with  movement  amplitude, 
when subjects write a single standard word. This method has 
high sensitivity and high ability to distinguish normal sub-
jects  from  those  with  idiopathic  or  drug-induced  parkin-
sonism. Dose-response effects have yet to be published. For 
the purpose of theory-testing it is preferable to evaluate the 
test  first  using  pharmacologically-simpler  drugs,  such  as 
haloperidol. This might then lead to the test being used in 
clinical practice in the following way: Patients are admitted 
to  hospital  in  acute  psychotic  states.  In  the  initial  “test” 
phase of management, lasting no more than one or two days, 
their disturbed state is checked without using antipsychotic 
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phase, small doses of haloperidol are given, and the change 
in  their  motor  performance  is  assessed  using  a  quantified 
version of the handwriting test. As a result, individual sensi-
tivity to antipsychotic drugs is determined. For the therapeu-
tic phase of management of the patient’s illness, this measure 
is  then  used  to  indicate  optimal  individualized  dose  of  a 
regular medication (such as an atypical drug), rather than the 
current “standard” doses based on “group averages”.  
  A few studies have been published showing the relation-
ship between clinical efficacy and plasma levels for atypical 
antipsychotic  drugs  (risperidone,  in  maintenance  treatment 
of chronic schizophrenia patients [75], and olanzapine [76]). 
At present there are insufficient data for such drugs to draw 
meaningful conclusions from plots such as those shown in 
Fig. 2. However, with a sensitive quantitative test [13], mo-
tor side effects of atypical drugs may also be quantifiable, 
and used to guide decisions about individual doses. 
  A related issue is whether optimal, or minimum-effective 
doses  needed  for  stable  relapse-free  maintenance  are  the 
same as or smaller than those needed in treatment of acute 
psychosis. Miller [87] presented a tentative case that mainte-
nance was possible with smaller doses than required in the 
phase of acute illness. However, the differential was small 
and the evidence-base quite  limited. No studies define the 
lower limit of plasma levels of any antipsychotic drug com-
patible with relapse-free maintenance. Thus, empirically the 
issue  is unresolved. Nevertheless,  a recent paper [39] pro-
vides a theoretical base supporting the differential suggested 
by Miller [87]. The argument starts from data in undrugged 
subjects [2], showing that normal occupancy of D2 receptors 
by dopamine is ~8.8%, compared with ~15.8% in a sample 
of  subjects  experiencing  psychotic  exacerbation  (with  en-
hanced dopamine release). If D2-blocking drugs are given to 
such patients to reduce occupancy by dopamine to normal 
levels, the required occupancy by the drug is 48%. However, 
assuming that dopamine and the antipsychotic drug compete 
for the same receptor sites, and  also (as  is probable),  that 
excess dopamine release is a transient consequence of psy-
chosis, rather than an enduring feature of schizophrenia, cal-
culations based on dopamine occupancy levels during psy-
chosis  would  overestimate  the  required  occupancy  by  the 
drug  during  maintenance  therapy.  In  maintenance,  lower 
doses would then suffice than in alleviation of acute illness. 
4. POINTS NOT RESOLVED, AND SUBSIDIARY IM-
PLICATIONS 
  If the foregoing theory is correct it requires reinterpreta-
tion  of  some  earlier  work,  and  other  issues  are  left  unre-
solved: 
(i)  In  estimating  D2  occupancy  by  antipsychotic  drugs 
assumptions  are  made  about  total  number  of  striatal 
dopamine  D2  receptors  (whether  or  not  occupied  by 
drugs) based on averaged data in normal subjects. Drug 
occupancy in patients is derived from the extent of ra-
dio-ligand binding (in the caudate-putamen) in patients, 
subtracted from that in undrugged controls. The differ-
ence is used to calculate binding in patients by the an-
tipsychotic drug. However, if  the foregoing theory is 
correct, the total number of receptors in  the striatum 
will be reduced in patients refractory to, or with low 
sensitivity to neuroleptic drugs [131]. As a result total 
available receptors are overestimated, and the fraction 
of available receptors binding to a ligand is underesti-
mated in such patients. The drug-bound fraction is then 
overestimated.  There  are  some  indications  of  this  in 
previous studies: (i) It was reported [20] that average 
occupancy of D2 receptors in 6 refractory patients, re-
ceiving typical neuroleptic drugs was 97% (range: 92-
100%).  The  low  ligand  binding  in  the  patients,  from 
which these values were derived, may have reflected, in 
part, low receptor numbers rather than high occupancy 
by the drug. (ii) It is also claimed [21,46] that D2 occu-
pancy is similar in groups of responsive and refractory 
patients, despite the fact that the latter received larger 
drug doses the former. Such results may have arisen 
because the refractory patients had fewer D2 receptors, 
compensated  by  the  fact  that  they  were  more  com-
pletely occupied than in the other patients. (iii) It was 
reported that, after discontinuation of a depot neurolep-
tic drug (haloperidol decanoate), computed D2 receptor 
occupancy  did  not  fall  back  rapidly  to  normal.  Even 
twelve  months  later  it  was  estimated  as  20%  [94a]. 
 
 
 
 
 
 
 
Fig. (3). Diagram to illustrate one possible interpretation of spread of data points in Fig. (2)A. Left: a number of S-shaped individual 
dose response curves, each “blurred” in the vertical dimension, are displaced to different degrees in horizontal dimension (representing dif-
ferent individual sensitivities to neuroleptic drugs). Right: If all the curves in the left-hand diagram are standardized to the individual “neuro-
leptic threshold, so that they all overlap, the distinction between “responders” and “non-responders” becomes clearer. Mechanisms of Action of Antipsychotic Drugs  Current Neuropharmacology, 2009, Vol. 7, No. 4    325 
However, this result, based on reduced ligand binding, 
might indicate loss of D2 receptors rather than contin-
ued occupancy of them by drugs.  The method might 
even  allow  detection  of  progressive  loss  of  receptors 
during  prolonged  high-dose  treatment,  although,  for 
ethical reasons, this cannot be done in a planned way. 
(ii)  In discussion of specific atypical drugs with potential 
clozapine-like  properties,  some  uncertainties  and  in-
consistencies about receptor affinities remain in avail-
able data, and there are uncertainties in their functional 
neurochemical effects (whether they are agonists,  an-
tagonists, or partial agonists). More data are needed on 
affinities of isomers of mesoridazine and thioridazine, 
especially for M1 and M4 muscarinic receptors, to clar-
ify whether any of these are safer alternatives to clo-
zapine.  More basic data on  the receptor-binding pro-
files  and  functional  effects  of  quetiapine  are  also 
needed, possibly  including receptors other  than  those 
considered here, to clarify its distinctive mode of ac-
tion. 
(iii)  Several interrelated questions remain unanswered about 
5HT2a receptors: How do 5HT2a receptors contribute 
to the low incidence of motor side effects in antipsy-
chotic drugs with the “SDA” profile? To answer that 
question, more basic questions must first be answered: 
What is the cytological location of the 5HT2a recep-
tors? What is their action at the cellular or subcellular 
level? 
  A single study [101] provides information about the cel-
lular location of 5HT2a receptors in the striatum. They are 
found predominantly in the dendrites (but rarely in dendritic 
spines) of cells identified as spiny neurones. Some of these 
receptors were also located on axon terminals, which, when 
identified, were similar to excitatory glutamatergic afferents 
to the striatum. No mention is made of 5HT2a receptors on 
elements  identified  as  somata  or  axons  of  cholinergic  in-
terneurones. There appear to be no electrophysiological data 
from  which  cellular  actions  of  5HT2a  antagonists  in  the 
striatum can be inferred. However, some indirect functional 
evidence in humans leads one to suspect that 5HT2a antago-
nists  act  at  a  target  “downstream”  from  the  D2  dopamine 
receptors. Thus, motor side effects produced by olanzapine 
are less than those produced by haloperidol at equivalent D2 
occupancy [80,98]. Two studies [61,118] find that, for pa-
tients with equal levels of D2 receptor occupancy, motor side 
effects are usually more severe if the drug used is haloperi-
dol  than  if  it  is  one  of  several  “SDA”  type  antipsychotic 
drugs. However, with risperidone, the severity of side effects 
was not much less than with haloperidol at equivalent occu-
pancy (see also [66,94b]). In the case of olanzapine, the lack 
of motor side effects may be due in part to action at mus-
carinic receptors (PART I, Table 1). Apart from olanzapine 
and risperidone, the evidence suggests that other drugs in the 
“SDA” class owe their relative lack of motor side effects to 
the fact that consequences of D2 blockade (presumably on 
the cholinergic interneurones) are reduced by actions “down-
stream”  from  this  primary  target.  Arguments  presented 
above suggest that motor side effects arise from the actions 
of  ACh  on  muscarinic  M1  receptors  located  on  medium 
spiny neurones. This implies that there may be an intracellu-
lar site in such neurones where effects produced by M1 and 
5HT2a  receptors  interact  synergistically,  such  that  5HTa 
antagonists mitigate the effects of stimulation of M1 recep-
tors by endogenous ACh. 
  Apart from  their low  tendency  to produce  acute  motor 
side effects, atypical drugs of the SDA type also have a low 
risk (compared to classical neuroleptic drugs) of producing 
the more serious motor side effects, such as tardive dyskine-
sia, during long term administration [74]. It has been pro-
posed that these more-or-less irreversible conditions are also 
the result of progressive loss of cholinergic interneurones, as 
a result of their prolonged overactivity, and associated acute 
motor side effects [89]. For clozapine the  low risk can be 
understood on the basis of this hypothesis, and the related 
theory, because the therapeutic action of this drug does not 
depend  on  D2  blockade  and  such  prolonged  overactivity. 
However,  for  other  atypical  drugs  with  an  uncomplicated 
“SDA”  profile,  the  therapeutic  actions  do  still  apparently 
depend on D2 blockade, and so would be expected to be as-
sociated with risk of developing tardive dyskinesia, regard-
less of the low risk of acute motor side effects. Tardive dy-
skinesia with these drugs is sometimes observed [117], but 
the risk is lower than with classical neuroleptic drugs. This is 
paradoxical in the light of the theory presented here: If their 
therapeutic action depends on blockade of dopamine D2 re-
ceptors, and the effect of concomitant 5HT2a antagonism is 
exerted “downstream” from the cholinergic neurones, these 
drugs would still be expected to lead to cholinergic cell loss. 
However, motor side effects, while due primarily to simple 
blockade  of  D2  receptors,  and  overactivity  of  cholinergic 
interneurones, may perhaps be intensified by some sort of 
positive feedback loop, involving neural activity in the me-
dium spiny neurones, and connectional loops through basal 
ganglia,  thalamus  and  cortex,  feeding  back  to  the  striatal 
cholinergic  interneurones.  Breaking  this  loop,  possibly  by 
the  action  of  5HT2a  antagonists  acting  on  medium  spiny 
neurones, could then reduce the excess activity in the cho-
linergic neurones, even if such drugs have no direct action 
on those neurones. 
5.  SUMMARY,  SUGGESTIONS  FOR  PRESCRIBING 
PRACTICE,  AND  PREDICTIONS  FOR  ADVANCE-
MENT  OF  SCIENTIFIC  UNDERSTANDING  OF  
ANTIPSYCHOTIC DRUGS 
  Despite the undoubted therapeutic role of antipsychotic 
drugs, many issues remain unresolved about their mode of 
action. These include the receptor type(s) which are the ulti-
mate target of these drugs, the reasons for lack of response in 
some  patients  with  psychotic  conditions,  the  individual 
variation  in  sensitivity  to  their  beneficial  effects,  and  the 
shape of the dose-response curve. The present paper builds 
upon  earlier  theoretical  work,  to  address  these  issues,  and 
argues for the following propositions: 
(i)  Although  therapeutic  potency  for  most  antipsychotic 
drugs scales with affinity for dopamine D2 receptors, 
several pieces of evidence do not fit their being the ul-
timate target. These suggest that D2-blocking drugs act 
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ing the dopamine D1 receptors (and others) which can 
control the mechanisms for synthesis of cyclic AMP. 
(ii)  Motor  side  effects  of  the  classical  neuroleptic  drugs 
depend on disinhibition of striatal cholinergic interneu-
rones, leading to increased ACh release, with side ef-
fects probably depending on actions at muscarinic M1 
receptors, located on principal neurones of the striatum. 
Muscarinic M4 receptors located on the same neurones 
suppress cAMP formation if this is activated from an-
other source. The net effect of stimulating these recep-
tors  is  similar  to  that  produced  by  dopamine  D1  an-
tagonists. It is proposed that this is the site at which 
classical  neuroleptic  drugs  exert  their  indirect  action, 
leading to their therapeutic benefits. 
(iii)  It is well established that many patients with psychotic 
illnesses fail to benefit from classical neuroleptic drugs. 
Sometimes this feature is present right at the start of the 
illness,  while  in  other  cases  it  emerges  during,  and 
probably as a result of prolonged neuroleptic treatment 
(“neuroleptic-induced supersensitivity psychosis”). For 
patients who do respond favourably, there is wide (at 
least ten-fold) variation of individual optimal or mini-
mum-effective doses. These inter-subject variations do 
not  appear  to  have  a  basis  in  pharmacokinetics,  but 
arise from variation in responsiveness within the brain. 
The source of uncontrolled variation is “downstream” 
from the dopamine D2 receptors, at which these drugs 
exert their direct actions. It is proposed that this unac-
counted source of variation is the density of cholinergic 
interneurones in relevant parts of the striatum, patients 
becoming more refractory or insensitive to the antipsy-
chotic effects, the lower the density of these neurones. 
Differences  in  neuroleptic  sensitivity,  and  density  of 
striatal cholinergic interneurones in different strains of 
mice support this proposal. Low density of striatal cho-
linergic  interneurones  may  also  predispose  patients 
with  Parkinson’s  disease  to  dyskinesias  during  treat-
ment with dopamine agonists. Tardive dyskinesia aris-
ing  during  long-term  neuroleptic  treatment  probably 
has a similar pathological basis. 
(iv)  There is evidence that the drug clozapine has actions at 
muscarinic M4 receptors as an agonist, with higher af-
finity  than  for  either  D1  or  D2  dopamine  receptors. 
This can account for its action in refractory psychosis, 
where the indirect mode of action via the cholinergic 
interneurones is no longer available. The effectiveness 
of this drug against dyskinesia or psychosis in Parkin-
son’s disease patients also follows from reasoning de-
veloped here. 
(v)  A  further  singular  feature  of  clozapine  is  that  rapid-
onset severe psychotic rebound is common on discon-
tinuation of the drug. This is to be expected from the 
mechanism proposed above for its action: Drugs which 
act directly on a target receptor will cause compensa-
tory  changes  in  receptor  number,  revealed  as  with-
drawal syndromes on discontinuation. Ones which act 
indirectly are less likely to produce such an effect. 
  From  the  theory  developed  here  the  question  is  raised 
whether drugs other than clozapine, already in use for many 
years might have the same favourable profile as clozapine 
(but without the danger of agranulocytosis, which may ne-
cessitate its discontinuation). The drugs for which this possi-
bility  is  most  likely  are  thioridazine  and  mesoridazine  (or 
one of their optical isomers). The drug quetiapine fulfils sev-
eral of the criteria for a clozapine-like drug, but, from pres-
ently-available data, does not have high relative affinity for 
either the D1 or M4 receptors. Its status  is enigmatic, but 
might indicate a usefulness in cases of refractory psychosis 
for which even clozapine is ineffective. In any case, because 
of the risk of rapid-onset withdrawal psychosis, clozapine or 
any other drugs in the same class, should not be the first-line 
treatment  for  psychosis,  but  should  be  reserved  only  for 
proven cases of non-responsiveness to standard drugs. 
Several predictions follow from the theory presented here:  
(i)  It is expected that dopamine-mediated synaptic change 
in the striatum is partly dependent on reduced choliner-
gic activation of muscarinic M4 receptors, located on 
medium spiny neurones. 
(ii)  The  presence  of  tardive  dyskinesia,  supersensitivity 
psychosis (or other sorts of refractory psychosis), and 
(in Parkinson’s disease) L-DOPA-induced dyskinesias, 
should correlate with low density of striatal cholinergic 
interneurones, and cholinergic markers. It may be pos-
sible to develop scanning methods for quantifying such 
markers, to test this prediction in vivo. 
(iii)  In rodent strains which show catalepsy without a phar-
macological  trigger,  there may be an unusually  large 
number  of  striatal  cholinergic  interneurones.  Those 
with a small number of such neurones may have a low 
threshold for “stereotypy” induced by stimulant drugs. 
(iv)  More binding data  are needed for some of the drugs 
with suspected clozapine-like pharmacological profiles, 
and also more data are needed to define whether some 
drugs acting  at  M1 and  M4  muscarinic receptors are 
agonists, partial agonists, or antagonists. 
(v)  The  relation  between  plasma  levels  of  antipsychotic 
drugs and clinical responses show a wide spread in the 
response measures at any effective plasma level. The 
“neuroleptic threshold” concept of Haase suggests that 
the dose producing the least detectable motor side ef-
fects  (for  typical  neuroleptic  drugs)  is  also  the  dose 
producing  all,  or  most  of  the  therapeutic  benefit,  al-
though in this paper it is argued that this is not a sharp 
all-or-none effect. It is suggested that the clinical re-
sponse might become distinctly bimodal (correspond-
ing  to  responder  versus  non-responder  status),  if  re-
sponses are standardised with respect to individual neu-
roleptic  threshold  (rather  dose  or  plasma  level).  A 
method is suggested by which quantitative determina-
tion of the individual threshold might be used to deter-
mine individualized optimal doses for the modern gen-
eration of antipsychotic drugs. 
(vi)  Suggestions are made  about  methodological errors  in 
estimation of drug occupancy of dopamine D2 recep-
tors  when  these  estimates  are  made  in  neuroleptic-
refractory or insensitive patients. The possible reasons Mechanisms of Action of Antipsychotic Drugs  Current Neuropharmacology, 2009, Vol. 7, No. 4    327 
why atypical drugs of the “serotonin-dopamine antago-
nist” class (other than clozapine) have a low incidence 
of motor side effects are also discussed. 
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